<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03342560</url>
  </required_header>
  <id_info>
    <org_study_id>2017P000940</org_study_id>
    <nct_id>NCT03342560</nct_id>
  </id_info>
  <brief_title>Beyond Confounders: Addressing Source of Measurement Variability and Error in Shear Wave Elastography</brief_title>
  <official_title>Beyond Confounders: Addressing Source of Measurement Variability and Error in Shear Wave Elastography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canon Medical Systems</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Siemens Medical Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radiological Society of North America</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic liver disease is a major problem in the general population and there is an unmet need
      to diagnose(and screen) for liver disease with using noninvasive, cost-effective and
      sensitive techniques.The investigators hypothesize that variation using ultrasound
      elastography for the estimation of stage of liver fibrosis and steatosis in patients with
      diffuse liver disease exists due to different methods of measurements, and/or different
      systems. The proposed investigation is a cross-sectional study using ultrasound elastography
      and fat quantification modalities. The investigators are planning to enroll 30 subjects 18
      years old and older in whom diffuse liver disease is suspected, and who have undergone
      non-focal liver biopsy in the past 6 months or are scheduled to undergo biopsy within 3
      months of enrollment, as part of their routine clinical care. The investigators will use 4
      different ultrasound devices with their shear wave elastography and speed of sound functions.

      Specific aims;

        -  Compare shear wave elastography(SWE) measurements from different ultrasound systems;
           using histopathology as reference standards.

        -  Assess intra-operator and inter-operator reliability by measuring variability in
           elastography values by two operators on a single system.

        -  Determine the effect of deviations from guidelines(less number of measurements and
           measurements during active breath)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liver disease and cirrhosis are important causes of morbidity and mortality in the United
      States and are a major public health problem with 40,000 deaths and more than 1.4 billion
      dollars spent on medical services. Hepatic fibrosis is the final common pathway for many
      different liver insults and is known to be a dynamic process, which is reversible if
      diagnosed early and treated. If untreated, fibrosis eventually progresses to cirrhosis, which
      is irreversible. The diagnosis of fibrosis relies on liver biopsy (the gold standard)
      however, is an invasive procedure with risks and sampling errors. Indirect biomarkers of
      fibrogenesis can measure some of these components to determine categories of fibrosis, with a
      sensitivity and specificity of 47% and 90% respectively.It is shown in the literature that,
      fat content of liver is related with fibrosis development. Biopsy is accepted as the most
      accurate technique to assess liver fat and fibrosis amount.

      Fibrotic livers demonstrate increased stiffness, a property that can be measured using
      technology named Ultrasound Elastography or sonoelastography (SWE). SWE is performed by
      insonating the patient with a low energy, amplitude, and frequency shear wave created by a
      vibrating probe. The propagated wave travels faster with increasing fibrosis: the stiffer the
      tissue, the faster the shear wave propagates. A pulse-echo ultrasound acquisition allows
      measurement of the wave velocity and the results are presented as kilopascals (kPa). Prior
      reports have described sensitivity and specificity for liver fibrosis detection of 80% and
      97% respectively for SWE. The benefits of SWE are that it is inexpensive, reproducible,
      painless, rapid (&lt; 10 min), easy to perform, and can be used for diagnosis, prognosis and
      monitoring disease progression.

      The objective of this study is to compare the variation in elastography values and study the
      factors that might cause these variations.

      The proposed investigation is a cross-sectional study using ultrasound elastography. The
      investigators are planning to enroll 30 subjects 18 years old and older in whom diffuse liver
      disease is suspected, and who have undergone non-focal liver biopsy in the past 6 months or
      are scheduled to undergo biopsy within 3 months of enrollment, as part of their routine
      clinical care.

      All subjects will be required to come to the MGH main campus for 2 study visits within 60
      days of each other. In addition, subjects will need to fast for at least 4 hours prior to
      study visits

      There will be two visits in this study and maximum 60 days time frame between the visits is
      anticipated. Two operators will perform the ultrasound examination. Reproducibility and
      repeatability of the ultrasound devices will be estimated.

      Ultrasound examination including sonoelastography will be performed using four FDA-approved
      ultrasound units; Both operators will perform;

        -  Median Elastograpy (10 measurements) on regular and variable map at a depth(in the area
           between 2cm from capsule and 6.5cm from skin)

        -  Median SWE value with active/free breath(10measurements)

        -  Median SWE value with less number of acquisitions(3measurements)

      These measurements will be collected in subgroups using specific systems. In second visit,
      all measurements will be repeated with the same operators.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 29, 2017</start_date>
  <completion_date type="Actual">August 30, 2018</completion_date>
  <primary_completion_date type="Actual">August 14, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Deviations From Suggested Guidelines- Any Effect on Agreement</measure>
    <time_frame>Visit 1 and Visit 2, an average of 2.5 hours for each visit</time_frame>
    <description>We collected guideline suggested shear wave elastography measurements from 20 patients. Guidelines suggest collecting 1) 10 measurements, 2) Asking patient to hold breath during the measurements. As a deviation from guideline suggestions, we collected measurements during free breath movements without asking patient to hold breath. As a deviation from the guideline suggestions, fewer number of measurements (3 measurements) were collected with asking the patient to hold breath during the measurements. All measurements were collected using one type of ultrasound system. All measurements were collected by 2 operators in 2 visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interoperator and Intraoperator Agreement in m/s and kPA Units</measure>
    <time_frame>Visit 1 and Visit 2, an average of 2.5 hours for each visit</time_frame>
    <description>In 20 patients we collected 10 shear wave elastography measurements in m/s and kPA units. Using one of the available ultrasound systems, 2 operators collected these measurements in 2 visits. Theoretically, m/s to kPA conversion can be made using an equation. However, some systems provide opportunity to get data in both units. Although algebraically m/s and kPA can be converted to each other, we found some minor differences in terms of inter-operator and intra-operator agreement.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Liver Fibrosis</condition>
  <condition>Liver Diseases</condition>
  <arm_group>
    <arm_group_label>30 Patients with known liver biopsy results</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with chronic liver disease with known biopsy results</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sonographic SWE measurements with 4 different ultrasound systems</intervention_name>
    <description>Sonographic Shear wave elastography will be performed to quantify liver fibrosis</description>
    <arm_group_label>30 Patients with known liver biopsy results</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult Patients

          -  Men or Woman

          -  Suspected diffuse liver disease and have had a liver biopsy within the last 6 months
             or are scheduled for a liver biopsy in the next 3 months.

          -  Consent to participate in the study

        Exclusion Criteria:

          -  Pregnancy

          -  Acute illness/ cognitive impairment resulting in inability to cooperate with
             ultrasound

          -  Patients that do not consent to ultrasound examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony E. Samir, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Medical Director, Ultrasound Imaging Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011 Jun;9(6):524-530.e1; quiz e60. doi: 10.1016/j.cgh.2011.03.020. Epub 2011 Mar 25.</citation>
    <PMID>21440669</PMID>
  </reference>
  <reference>
    <citation>Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, Murray CJ, Naghavi M. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014 Sep 18;12:145. doi: 10.1186/s12916-014-0145-y.</citation>
    <PMID>25242656</PMID>
  </reference>
  <reference>
    <citation>Pinzani M, Rombouts K. Liver fibrosis: from the bench to clinical targets. Dig Liver Dis. 2004 Apr;36(4):231-42. Review. Erratum in: Dig Liver Dis. 2004 Aug;36(8):562-3.</citation>
    <PMID>15115333</PMID>
  </reference>
  <reference>
    <citation>Schölmerich J, Holstege A. Aetiology and pathophysiology of chronic liver disorders. Drugs. 1990;40 Suppl 3:3-22. Review.</citation>
    <PMID>2081479</PMID>
  </reference>
  <reference>
    <citation>Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol. 2014 Mar;14(3):181-94. doi: 10.1038/nri3623. Review.</citation>
    <PMID>24566915</PMID>
  </reference>
  <reference>
    <citation>Actis GC, Olivero A, Lagget M, Pellicano R, Smedile A, Rizzetto M. The practice of percutaneous liver biopsy in a gastrohepatology day hospital: a retrospective study on 835 biopsies. Dig Dis Sci. 2007 Oct;52(10):2576-9. Epub 2007 Apr 12.</citation>
    <PMID>17436094</PMID>
  </reference>
  <reference>
    <citation>Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology. 2000 Sep;32(3):477-81.</citation>
    <PMID>10960438</PMID>
  </reference>
  <reference>
    <citation>van der Poorten D, Kwok A, Lam T, Ridley L, Jones DB, Ngu MC, Lee AU. Twenty-year audit of percutaneous liver biopsy in a major Australian teaching hospital. Intern Med J. 2006 Nov;36(11):692-9.</citation>
    <PMID>17040353</PMID>
  </reference>
  <reference>
    <citation>Sparchez Z. Complications after percutaneous liver biopsy in diffuse hepatopathies. Rom J Gastroenterol. 2005 Dec;14(4):379-84. Review.</citation>
    <PMID>16400355</PMID>
  </reference>
  <reference>
    <citation>Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001 Feb 15;344(7):495-500. Review.</citation>
    <PMID>11172192</PMID>
  </reference>
  <reference>
    <citation>Rousselet MC, Michalak S, Dupré F, Croué A, Bedossa P, Saint-André JP, Calès P; Hepatitis Network 49. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology. 2005 Feb;41(2):257-64.</citation>
    <PMID>15660389</PMID>
  </reference>
  <reference>
    <citation>Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002 Oct;97(10):2614-8.</citation>
    <PMID>12385448</PMID>
  </reference>
  <reference>
    <citation>Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003 Dec;38(6):1449-57.</citation>
    <PMID>14647056</PMID>
  </reference>
  <reference>
    <citation>Friedrich-Rust M, Buggisch P, de Knegt RJ, Dries V, Shi Y, Matschenz K, Schneider MD, Herrmann E, Petersen J, Schulze F, Zeuzem S, Sarrazin C. Acoustic radiation force impulse imaging for non-invasive assessment of liver fibrosis in chronic hepatitis B. J Viral Hepat. 2013 Apr;20(4):240-7. doi: 10.1111/j.1365-2893.2012.01646.x. Epub 2012 Jul 31.</citation>
    <PMID>23490368</PMID>
  </reference>
  <reference>
    <citation>Fierbinteanu-Braticevici C, Andronescu D, Usvat R, Cretoiu D, Baicus C, Marinoschi G. Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis. World J Gastroenterol. 2009 Nov 28;15(44):5525-32.</citation>
    <PMID>19938190</PMID>
  </reference>
  <reference>
    <citation>Ferraioli G, Tinelli C, Dal Bello B, Zicchetti M, Filice G, Filice C; Liver Fibrosis Study Group. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. Hepatology. 2012 Dec;56(6):2125-33. doi: 10.1002/hep.25936. Epub 2012 Aug 31.</citation>
    <PMID>22767302</PMID>
  </reference>
  <reference>
    <citation>Poynard T, Munteanu M, Luckina E, Perazzo H, Ngo Y, Royer L, Fedchuk L, Sattonnet F, Pais R, Lebray P, Rudler M, Thabut D, Ratziu V. Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard. J Hepatol. 2013 May;58(5):928-35. doi: 10.1016/j.jhep.2012.12.021. Epub 2013 Jan 12.</citation>
    <PMID>23321316</PMID>
  </reference>
  <reference>
    <citation>Chen S, Sanchez W, Callstrom MR, Gorman B, Lewis JT, Sanderson SO, Greenleaf JF, Xie H, Shi Y, Pashley M, Shamdasani V, Lachman M, Metz S. Assessment of liver viscoelasticity by using shear waves induced by ultrasound radiation force. Radiology. 2013 Mar;266(3):964-70. doi: 10.1148/radiol.12120837. Epub 2012 Dec 6.</citation>
    <PMID>23220900</PMID>
  </reference>
  <reference>
    <citation>Goertz RS, Zopf Y, Jugl V, Heide R, Janson C, Strobel D, Bernatik T, Haendl T. Measurement of liver elasticity with acoustic radiation force impulse (ARFI) technology: an alternative noninvasive method for staging liver fibrosis in viral hepatitis. Ultraschall Med. 2010 Apr;31(2):151-5. doi: 10.1055/s-0029-1245244. Epub 2010 Mar 19.</citation>
    <PMID>20306380</PMID>
  </reference>
  <reference>
    <citation>Takahashi H, Ono N, Eguchi Y, Eguchi T, Kitajima Y, Kawaguchi Y, Nakashita S, Ozaki I, Mizuta T, Toda S, Kudo S, Miyoshi A, Miyazaki K, Fujimoto K. Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease: a pilot study. Liver Int. 2010 Apr;30(4):538-45. doi: 10.1111/j.1478-3231.2009.02130.x. Epub 2009 Oct 27.</citation>
    <PMID>19874490</PMID>
  </reference>
  <reference>
    <citation>Friedrich-Rust M, Wunder K, Kriener S, Sotoudeh F, Richter S, Bojunga J, Herrmann E, Poynard T, Dietrich CF, Vermehren J, Zeuzem S, Sarrazin C. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology. 2009 Aug;252(2):595-604. doi: 10.1148/radiol.2523081928.</citation>
    <PMID>19703889</PMID>
  </reference>
  <reference>
    <citation>Wang QB, Zhu H, Liu HL, Zhang B. Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: A meta-analysis. Hepatology. 2012 Jul;56(1):239-47. doi: 10.1002/hep.25610. Epub 2012 Jun 6. Review.</citation>
    <PMID>22278368</PMID>
  </reference>
  <reference>
    <citation>Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006 Jun;43(6):1317-25.</citation>
    <PMID>16729309</PMID>
  </reference>
  <reference>
    <citation>Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konaté A, Gallois Y, Ternisien C, Chevailler A, Lunel F. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005 Dec;42(6):1373-81.</citation>
    <PMID>16317693</PMID>
  </reference>
  <reference>
    <citation>Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, Farrell G, McCaughan GW, Jeffrey GP. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005 Oct;51(10):1867-73. Epub 2005 Jul 28.</citation>
    <PMID>16055434</PMID>
  </reference>
  <reference>
    <citation>Forns X, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, Bruguera M, Sánchez-Tapias JM, Rodés J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002 Oct;36(4 Pt 1):986-92.</citation>
    <PMID>12297848</PMID>
  </reference>
  <reference>
    <citation>Crespo G, Fernández-Varo G, Mariño Z, Casals G, Miquel R, Martínez SM, Gilabert R, Forns X, Jiménez W, Navasa M. ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study. J Hepatol. 2012 Aug;57(2):281-7. doi: 10.1016/j.jhep.2012.03.016. Epub 2012 Apr 17.</citation>
    <PMID>22521355</PMID>
  </reference>
  <reference>
    <citation>Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ; European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004 Dec;127(6):1704-13.</citation>
    <PMID>15578508</PMID>
  </reference>
  <reference>
    <citation>Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003 Aug;38(2):518-26.</citation>
    <PMID>12883497</PMID>
  </reference>
  <reference>
    <citation>Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T; MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001 Apr 7;357(9262):1069-75.</citation>
    <PMID>11297957</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 6, 2017</study_first_submitted>
  <study_first_submitted_qc>November 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <results_first_submitted>August 27, 2019</results_first_submitted>
  <results_first_submitted_qc>October 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 28, 2019</results_first_posted>
  <last_update_submitted>October 5, 2019</last_update_submitted>
  <last_update_submitted_qc>October 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Anthony Samir</investigator_full_name>
    <investigator_title>Service Chief,Body Ultrasound Department of Radiology, Assistant Professor at Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>Liver Fibrosis</keyword>
  <keyword>Ultrasound Elastography</keyword>
  <keyword>Shear wave speed</keyword>
  <keyword>Stiffness</keyword>
  <keyword>Liver Biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT03342560/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All 30 patients were scanned in clinic ultrasound setting. 2 visits were scheduled for each patient. Mean difference between visits was 11 days. Mean difference between liver biopsy date and first visit date was 89 days. 2 patients were lost to followup for 2nd visit.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Chronic Liver Disease Patients With Known Liver Biopsy Results</title>
          <description>Patients with chronic liver disease with known biopsy results
Sonographic SWE measurements with Toshiba/Canon APLIO500: Sonographic Shear wave elastography will be performed to quantify liver fibrosis
Sonographic SWE measurements with Siemens ACUSON S3000: Sonographic Shear wave elastography will be performed to quantify liver fibrosis
Sonographic SWE measurements with GE LOGIQ E9: Sonographic Shear wave elastography will be performed to quantify liver fibrosis
SWE measurements with FibroScan: Transient elastography will be performed to quantify liver fibrosis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>30 Patients With Known Liver Biopsy Results</title>
          <description>Patients with chronic liver disease with known biopsy results
Sonographic SWE measurements with Toshiba APLIO500: Sonographic Shear wave elastography will be performed to quantify liver fibrosis
Sonographic SWE measurements with Siemens ACUSON S3000: Sonographic Shear wave elastography will be performed to quantify liver fibrosis
Sonographic SWE measurements with GE LOGIQ E9: Sonographic Shear wave elastography will be performed to quantify liver fibrosis
SWE measurements with FibroScan: Transient elastography will be performed to quantify liver fibrosis
Sonographic speed of sound measurements with GE LOGIQ E9: Sonographic speed of sound function of the machine will be used to quantify liver steatosis</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="21" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fibrosis stage</title>
          <description>Fibrosis severity in the biopsy samples were staged using METAVIR system. Higher stages correspond to higher disease severity, and stage4 shows cirrhosis.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Fibrosis 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrosis 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrosis 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrosis 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrosis 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Deviations From Suggested Guidelines- Any Effect on Agreement</title>
        <description>We collected guideline suggested shear wave elastography measurements from 20 patients. Guidelines suggest collecting 1) 10 measurements, 2) Asking patient to hold breath during the measurements. As a deviation from guideline suggestions, we collected measurements during free breath movements without asking patient to hold breath. As a deviation from the guideline suggestions, fewer number of measurements (3 measurements) were collected with asking the patient to hold breath during the measurements. All measurements were collected using one type of ultrasound system. All measurements were collected by 2 operators in 2 visits.</description>
        <time_frame>Visit 1 and Visit 2, an average of 2.5 hours for each visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Guideline Suggested Measurements</title>
            <description>10 measurements in an area between 2cm from liver capsule and 6.5cm from skin</description>
          </group>
          <group group_id="O2">
            <title>Fewer Number of Measurements</title>
            <description>3 SWE measurements were collected.</description>
          </group>
          <group group_id="O3">
            <title>Free Breath Measurements</title>
            <description>10 SWE measurements were collected during free breath</description>
          </group>
        </group_list>
        <measure>
          <title>Deviations From Suggested Guidelines- Any Effect on Agreement</title>
          <description>We collected guideline suggested shear wave elastography measurements from 20 patients. Guidelines suggest collecting 1) 10 measurements, 2) Asking patient to hold breath during the measurements. As a deviation from guideline suggestions, we collected measurements during free breath movements without asking patient to hold breath. As a deviation from the guideline suggestions, fewer number of measurements (3 measurements) were collected with asking the patient to hold breath during the measurements. All measurements were collected using one type of ultrasound system. All measurements were collected by 2 operators in 2 visits.</description>
          <units>correlation coefficient</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ICC for inter-operator agreement in visit1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" lower_limit="0.45" upper_limit="0.90"/>
                    <measurement group_id="O2" value="0.75" lower_limit="0.40" upper_limit="0.90"/>
                    <measurement group_id="O3" value="0.69" lower_limit="0.26" upper_limit="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICC for inter-operator agreement in visit2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" lower_limit="0.64" upper_limit="0.94"/>
                    <measurement group_id="O2" value="0.80" lower_limit="0.48" upper_limit="0.92"/>
                    <measurement group_id="O3" value="0.68" lower_limit="0.20" upper_limit="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICCfor intra-op agreement between 2 visits for op1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" lower_limit="0.84" upper_limit="0.97"/>
                    <measurement group_id="O2" value="0.90" lower_limit="0.75" upper_limit="0.96"/>
                    <measurement group_id="O3" value="0.93" lower_limit="0.61" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICCfor intra-op agreement between 2 visits for op2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" lower_limit="0.74" upper_limit="0.96"/>
                    <measurement group_id="O2" value="0.89" lower_limit="0.73" upper_limit="0.96"/>
                    <measurement group_id="O3" value="0.95" lower_limit="0.87" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interoperator and Intraoperator Agreement in m/s and kPA Units</title>
        <description>In 20 patients we collected 10 shear wave elastography measurements in m/s and kPA units. Using one of the available ultrasound systems, 2 operators collected these measurements in 2 visits. Theoretically, m/s to kPA conversion can be made using an equation. However, some systems provide opportunity to get data in both units. Although algebraically m/s and kPA can be converted to each other, we found some minor differences in terms of inter-operator and intra-operator agreement.</description>
        <time_frame>Visit 1 and Visit 2, an average of 2.5 hours for each visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Measurements in m/s Unit</title>
            <description>In 20 patients, we collected 10 measurements at a depth between 2cm from liver capsule and 6.5 from skin.</description>
          </group>
          <group group_id="O2">
            <title>Measurements in kPA Unit</title>
            <description>In 20 patients, we collected 10 measurements at a depth between 2cm from liver capsule and 6.5 from skin.</description>
          </group>
        </group_list>
        <measure>
          <title>Interoperator and Intraoperator Agreement in m/s and kPA Units</title>
          <description>In 20 patients we collected 10 shear wave elastography measurements in m/s and kPA units. Using one of the available ultrasound systems, 2 operators collected these measurements in 2 visits. Theoretically, m/s to kPA conversion can be made using an equation. However, some systems provide opportunity to get data in both units. Although algebraically m/s and kPA can be converted to each other, we found some minor differences in terms of inter-operator and intra-operator agreement.</description>
          <units>Intraclass correlation coefficient value</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ICC for inter-operator agreement in visit1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" lower_limit="0.47" upper_limit="0.96"/>
                    <measurement group_id="O2" value="0.84" lower_limit="0.36" upper_limit="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICC for inter-operator agreement in visit2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" lower_limit="0.26" upper_limit="0.94"/>
                    <measurement group_id="O2" value="0.77" lower_limit="0.13" upper_limit="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICC for intra-operator agreement for opt1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" lower_limit="0.71" upper_limit="0.97"/>
                    <measurement group_id="O2" value="0.88" lower_limit="0.57" upper_limit="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICC for intra-operator agreement for opt2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="0.35" upper_limit="0.94"/>
                    <measurement group_id="O2" value="0.78" lower_limit="0.27" upper_limit="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were not expected for this study. 0 participants were at risk for this study. Adverse events were not collected.</time_frame>
      <desc>We used ultrasound systems and ultrasound is a very safe technique for liver evaluation. There are no expected risks for this technique. Therefore, all-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed. 0 participants were at risk for this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>30 Patients With Known Liver Biopsy Results</title>
          <description>Patients with chronic liver disease with known biopsy results
Sonographic SWE measurements with Toshiba APLIO500: Sonographic Shear wave elastography will be performed to quantify liver fibrosis
Sonographic SWE measurements with Siemens ACUSON S3000: Sonographic Shear wave elastography will be performed to quantify liver fibrosis
Sonographic SWE measurements with GE LOGIQ E9: Sonographic Shear wave elastography will be performed to quantify liver fibrosis
SWE measurements with FibroScan: Transient elastography will be performed to quantify liver fibrosis
Sonographic speed of sound measurements with GE LOGIQ E9: Sonographic speed of sound function of the machine will be used to quantify liver steatosis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Reference standard (biopsy) was collected from medical records. Pathology slides were not re-evaluated.
Low number of patients to perform diagnostic performance analysis</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Anthony E. Samir</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>6176432009</phone>
      <email>asamir@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

